Dose-dependent effects of vildagliptin (DPP-4 inhibitor) in a scopolamine-induced memory impairment model in rats

Key Points

• Memory impairment improved significantly with vildagliptin treatment, showing enhanced cognitive function.
• The study indicates that higher doses lead to greater improvements in memory deficits, specifically in the scopolamine model.
• Assessment using a scopolamine-induced memory impairment model highlights the role of vildagliptin as a DPP-4 inhibitor.
• Therapeutic effects are observed in this rat model; further research is needed to establish human applicability.